摘要
血管紧张素转化酶抑制剂(ACEi)在临床上是作为心血管和肾脏疾病比较安全的治疗药物,其毒副作用较少。近年来发现癌症病人长期使用ACEi可以降低癌症发病率和死亡率。体内外实验表明,ACEi可以抑制肿瘤生长和转移,抑制肿瘤血管生成和细胞外基质降解等。ACEi抗癌作用的机制涉及干扰RAS系统(主要是抑制血管紧张素转化酶活性),以及抑制基质金属蛋白酶(MMP)活性等。几个大样本的流行病学研究发现,ACEi抗癌效果受到ACE的2个基因多态性A-240T和插入/缺失(I/D)影响。在含有低风险等位基因(A和I)的人群中ACEi抗癌效果比较明显,但这一现象在各个种族中有较大差异,并且受到绿茶饮用量等因素影响。既然ACEi已经在临床上广泛使用而无严重毒副作用,这为我们提供了癌症治疗和化学防护的新策略。
Angiotensin-I converting enzyme inhibitors （ACEi） prescribed for cardiovascular and renal disease since 1980 are widely atoxic. Recently, it was reported that the long-term administration of ACE inhibitors reduces morbidity and mortality in cancer patients. The ACE inhibitors significantly inhibit tumor growth and angiogenesis and reduce proliferation and migration of cancer cells in experimental models of cancer. Several mechanisms of action are possible,including inhibition of matrix metallopro- tease activity and interference with the renin-angiotensin system. Several epidemiological studies suggested that the effects of ACEi on cancer are influenced by the ACE A - 240T and I/D gene polymorphisms. Man with the low activity allele（A and I） showed a reduced risk of cancer compared with those with high activity allele（T and D）. But the associations were not consistent across ethnic groups, and were influenced by some factors, such as green tea intake. Since ACEi are already in widespread clinical use without any serious adverse effects, they may represent a potential new strategy for cancer therapy and chemoprevention.
出处
《药物生物技术》
CAS
CSCD
2010年第2期172-176,共5页
Pharmaceutical Biotechnology
